Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Leveraging Bicycle Conjugates as Radio-Imaging & Theragnostic Agents to Inform Early Clinical Therapeutic Development

Leveraging Bicycle Conjugates as Radio-Imaging & Theragnostic Agents to Inform Early Clinical Therapeutic Development

12:00 pm - Wednesday 14th October 2026

Exploring human data generated from Gallium-68 imaging studies with Bicycle molecules
Laying out the latest preclinical data of Bicycle Drug Conjugates
Delving into Gallium-68 PET imaging with Bicycle Molecules to guide clinical development of therapeutic conjugates

Speakers:

Steve Walsh

Steve Walsh

Principal Scientist, Project Leader

Bicycle Therapeutics plc